HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chilton, R. J. Search for Related Content PubMed PubMed Citation Articles by Chilton, R. J.

Dr Chilton has received research support from the National Heart, Lung,and Blood Institute; Pfizer Inc; Takada Pharmaceuticals America, Inc; Johnson & Johnson; Boston Scientific; Aventis Pharmaceuticals Inc; Bristol-Myers Squibb Company; and Merck Sharpe & Dohme Research Laboratories.

Address correspondence to Robert J. Chilton, DO, FACC, FACOI, Associate Professor, Department of Medicine, Division of Cardiology, The University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78284-6200.E-mail: chilton{at}uthscsa.edu

Coronary heart disease (CHD) remains a persistent public health burden in the United States, and it is the cause of one of every five deaths each year. The link between lipids and CHD has been firmly established, first by epidemiologic studies and, more recently, by long-term outcomes trials that demonstrated that lowering low-density lipoprotein cholesterol (LDL-C) levels significantly reduced the risk of major coronary events. Based on this evidence, the National Cholesterol Education Program recommends lowering the LDL-C level to reduce CHD risk, particularly for patients at highest risk. Recently, evidence has emerged that suggests that C-reactive protein may be a mediator of atherosclerosis and its presence may be indicative of increased risk of CHD. Although these data are intriguing, their relevance has yet to be established in prospective outcomes trials. Until then, lipid lowering through lifestyle modification and the use of safe and effective modes of therapy should be the emphasis of CHD risk reduction strategies.

This article has been cited by other articles:

				J. L. Mehta, J. Chen, P. L. Hermonat, F. Romeo, and G. Novelli Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): A critical player in the development of atherosclerosis and related disorders Cardiovasc Res, January 1, 2006; 69(1): 36 - 45. [Abstract] [Full Text] [PDF]

				D. M. Mutch, W. Wahli, and G. Williamson Nutrigenomics and nutrigenetics: the emerging faces of nutrition FASEB J, October 1, 2005; 19(12): 1602 - 1616. [Abstract] [Full Text] [PDF]